Basic Information
| LncRNA/CircRNA Name | XIRP2-AS1 |
| Synonyms | NA |
| Region | GRCh38_2:167123904-167140955 |
| Ensemble | ENSG00000254552 |
| Refseq | NR_046665 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colon cancer |
| ICD-0-3 | C18 |
| Methods | qPCR, Western blot, RNAi, RIP, Microarray, Luciferase reporter assays, other |
| Sample | Colon cancer tissues and cell lines (SW620 and HCT116) |
| Expression Pattern | down-regulated |
| Function Description | LncRNA XIRP2-AS1 was significantly less expressed in colon cancer tissue. XIRP2-AS1 was remarkably downregulated in colon cancer tissues and cell lines. Functionally, XIRP2-AS1 could inhibit the proliferation and invasion ability of colon cancer cells in vitro and in vivo. Clinical sample analysis showed that XIRP2-AS1 had a favorable impact on the overall survival and progression free survival of patients with colon cancer. miR-182 was validated as the target of XIRP2-AS1 according to luciferase reporter assays, RNA immunoprecipitation and RNA pull down. |
| Pubmed ID | 31410022 |
| Year | 2019 |
| Title | The LncRNA XIRP2-AS1 Predicts Favorable Prognosis in Colon Cancer |
External Links
| Links for XIRP2-AS1 | GenBank HGNC NONCODE |
| Links for colon cancer | OMIM COSMIC |